SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to a significant drop following Phase 3 trial data, which, despite showing statistical significance in one analysis, was impacted by a high placebo response in another. The community is debating whether this drop is an overreaction, citing the company's cash runway, other pipeline products, and previous buyout rumors as reasons for potential recovery. Bullish investors believe long-term prospects remain strong, while others express concern over the trial results and potential implications for the company's future.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

$WEEDCOIN.X is trending as community members rally around the crypto's connection to cannabis culture and a shared vision of positivity. Advocates emphasize that $WEEDCOIN.X represents more than just a token; it's a movement towards freedom, community, and growth, aiming to bridge the gap between cannabis enthusiasts and the digital economy.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals ($ENTA) is trending as investors anticipate topline results from its Phase 2b study of Zelicapavir for RSV, expected to be released soon. Bullish sentiment is building, with some traders hoping for a significant price increase if the data proves positive. The community is actively seeking insights and analysis to gauge the potential outcome of the study.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending due to the appointment of Barbara Humpton as the new CEO, effective October 1, 2025; the community is discussing her extensive experience and the company's strategic focus on becoming a leading supplier of rare earth minerals and magnets. Conversations also involve speculation around government deals and potential investment, along with options activity and price targets.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to a recently announced private placement of approximately $44 million, leading to significant after-hours price movement. Community discussions revolve around the stock's small float, potential for a squeeze, and the impact of warrants associated with the deal. Some traders are optimistic about continued upward momentum, while others express concerns about potential dilution.

Advisorshares Trust - AdvisorShares MSOS 2x Daily ETF

AdvisorShares MSOS Daily Leveraged ETF

MSOX is trending as investors discuss potential catalysts for cannabis stocks, including regulatory reform and rescheduling. Community members are debating whether to buy and hold for long-term growth or trade on short-term price movements, while some are expressing frustration with the ETF's performance relative to its underlying assets. The broader context involves speculation around political developments and potential shifts in market sentiment towards the cannabis sector.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to recent surges in volume and price, sparking speculation about a potential short squeeze or upcoming news catalyst. Community discussions revolve around the possibility of significant upside, comparing it to similar stocks with low floats, while also referencing analyst upgrades and price target increases. The stock's volatility and potential for further gains are key talking points.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending as investors anticipate data from its nomlabofusp clinical development program for Friedreich's Ataxia, expected sometime this month. Community members are weighing the potential for positive results and a subsequent rise in stock price, while also considering the risk of negative outcomes given the high short interest and upcoming conference call to discuss updates. Some traders are noting unusual options activity, suggesting significant potential movement in either direction post-announcement.

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V

Merus is trending after Genmab announced its acquisition of the company for $97 per share, a deal valued at $8 billion, to gain access to a promising head and neck cancer drug. The community is buzzing about the buyout price and the strategic implications for Genmab as it aims to become a global biotech leader. Some traders are expressing regret for previously selling their shares while others are eyeing similar companies as potential takeover targets.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is trending as the community discusses the potential impact of cannabis rescheduling following Trump's recent comments and a new $50 million share repurchase program. Community talking points include tax relief, increased profitability for US cannabis companies, and advantages over Canadian competitors. Some investors view GTBIF as a strong, profitable US-based company poised to benefit from regulatory changes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Down 33.4% YTD, Can Select Medical Stitch Back its Growth Story?

After a 33.4% YTD drop, SEM battles rising costs and weak returns while its rehab unit and valuation keep optimism alive.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Pediatrix Medical Shares Are Attracting Investors Now

MD shares surge on strong earnings, rising revenues, cost cuts and a new $250M buyback plan.

Despite Fast-paced Momentum, Pediatrix Medical Group (MD) Is Still a Bargain Stock

Pediatrix Medical Group (MD) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Danaher Gains From Business Strength Amid Persisting Headwinds

DHR posts gains in bioprocessing, biotech and diagnostics, while life sciences softness and high debt weigh.

Zacks.com featured highlights include Post Holdings, Pediatrix Medical, Envista and Zions Bancorporation

Post Holdings, Pediatrix, Envista, and Zions Bancorporation hit 52-week highs as growth, cash flow, and upgrades fuel momentum.

Should You Buy Pediatrix Medical Group (MD) After Golden Cross?

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

4 Stocks Trading Near 52-Week High With Room to Rise Further

Investors target stocks that have been on a bullish run. Stocks like POST, MD, NVST and ZION are seeing price strength, and the momentum is likely to continue.

5 Stocks Scoring High on Relative Price Strength Metrics

MD, ENVA, PRIM, SKYW and AEM stand out with strong relative price strength and positive earnings revisions.

Pediatrix Medical Refills Its Buyback Prescription With $250M Dose

MD launches a $250M buyback, fueled by stronger cash flow, leaner operations and robust 2025 profit outlook.

Pediatrix Medical Group, Inc. engages in the provision of physician services. Its services include neonatal care, maternal fetal care, and other pediatric subspeciality care. The company was founded by Roger J. Medel in 1979 and is headquartered in Sunrise, FL.

MD
MEDNAX Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MD News

MD MEDNAX Inc